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Abstract
In this prospective, randomized, open-label clinical trial, we compared the efﬁcacy and safety of two antibiotic regimens for severe dia-
betic foot infections (DFI). Sixty-two in-patients with DFI received either piperacillin/tazobactam (Pip-Tazo, n = 30) (4.5 g intravenously
every 8h) or imipenem/cilastatin (IMP, n = 32) (0.5 g intravenously every 6h). The mean duration of treatment was 21 days for Pip-Tazo
and 24 days for IMP. Twenty-two (73.3%) patients in the Pip-Tazo group and 26 (81.2%) patients in the IMP group had DFI associated
with osteomyelitis. Successful clinical response was seen in 14 (46.7%) patients in the Pip-Tazo group and in nine (28.1%) patients in the
IMP group [relative risk (RR) 1.6 (95% CI 0.84–3.25), p 0.130]. Two patients in the IMP group and none in the PIP-Tazo group relapsed
[RR 2 (0.94–4.24), p 0.058]. Eighty-nine microorganisms were isolated: 38 (43%) Gram-positive and 51(57%) Gram-negative. Among
patients with positive culture, 47 (96%) had complete and two (4%) had partial microbiological response. Microbiological response rates
were similar in both groups (p 1.000). Amputation was performed in 18 (60%) and 22 (69%) patients in the Pip-Tazo and IMP groups
(p 0.739) respectively. Side effects were more common in the Pip-Tazo group (30% vs. 9.4%), but they were generally mild and revers-
ible. In conclusion, although the sample size was small and the results did not reach statistical signiﬁcance, Pip-Tazo produced a better
clinical response rate than IMP in the treatment of severe DFI. There was no signiﬁcant difference between the treatment groups with
respect to microbiological response, relapse and amputation rates.
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Introduction
Diabetic wound infection is the most common cause of
hospitalization in diatetic patients [1,2]. Severe diabetic
foot infections (DFIs) lead to extremity amputations,
reduced quality of life and mortality [3–7]. In addition to
proper local wound care, DFIs require carefully selected
antibiotic therapy. There are no speciﬁc recommendations
for the choice of antibiotics in DFI [8]. Evidence-based
reports and guidelines recommend that antibiotic therapy
should be started empirically and include broad-spectrum
cover [6,9]. Subsequent to empirical therapy, speciﬁc
agents should be selected according to the results of cul-
ture and sensitivity tests and the patient’s clinical response.
Parenteral administration is usually preferred to achieve
rapidly an adequate tissue concentration, particularly for
moderate to severe DFI. Antibiotics such as ampicillin-
sulbactam, piperacillin-tazobactam (Pip-Tazo), imipenem-
cilastatin (IMP) or ertapenem are usually recommended for
moderate to severe cases [3,4,6–11]. Although the efﬁcacy
of these agents is well-established in DFI, Pip-Tazo and
IMP have not been compared head-to-head with each
other before, particulary in patients with DFI associated
with osteomyelitis.
In the present study, we compared the efﬁcacy and safety
proﬁle of two parenteral antibiotic regimens, piperacillin-
tazobactam (Pip-Tazo) and imipenem-cilastatin (IMP), for the
treatment of moderate to severe DFI.
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Materials and Methods
Study design and population
This was a prospective, single-centre, two-arm, randomized,
open-label clinical trial, conducted in Cukurova University
Hospital between April 2004 and August 2006.
Eligible patients were hospitalized adults (age ‡18 years)
with a clinical diagnosis of moderate to severe diabetic lower
extremity infection (Wagner grade 2–4) caused by bacteria
known or suspected to be susceptible to Pip-Tazo or IMP.
Exclusion criteria were treatment with any potentially effec-
tive antibiotic within the previous 48 h, hypersensitivity to
any of the study medications, epilepsy, psychiatric illness, and
pregnancy or lactation. All eligible patients were included in
the study during a 2-year study period.
We used a random-number table prepared by Statistics
Department of Cukurova University to allocate the patients
to Pip-Tazo or IMP treatment arms. This table was kept by
the AD Infectious Diseases Department of Cukurova Univer-
sity and study personnel called the AD to allocate recruited
patients to study groups.
The study was approved by the Institutional Review Board
of Cukurova University Medical School (Local Ethics Com-
mittee). All study participants provided their written
informed consent before any study-related procedure. The
trial was not registered.
Study procedures
Medical history and physical examination ﬁndings of the
foot and other systems were recorded. Lesions were
assessed for purulent discharge, erythema, ﬂuctuation,
warmth, pain or tenderness, induration, depth of wound
and degree of soft tissue and bone involvement. The pres-
ence and extent of osteomyelitis were documented. Sam-
ples from skin biopsy, purulent secretions, debrided tissue
or ﬁne needle aspiration were cultured. In cases where a
surgical intervention was required, deep tissue or bone
biopsy material were cultured. Superﬁcial wound swabs
were not processed.
Optimal wound care was given by an experienced nurse,
who was a member of the study group. Vacuum assisted clo-
sure was applied when necessary.
Patients were followed with hematological, biochemical,
erythrocyte sedimentation rate and C-reactive protein values
on days 1, 7, 14 and 28 of treatment. To determine
microbiological response to therapy, follow-up cultures
were obtained on days 4–7 and at the end of therapy when
feasible.
All patients were followed for 2 months after discharge.
Study treatment
Eligible patients were randomized to receive one of the two
drugs [Pip-Tazo (Tazocin; Wyeth, Istanbul, Turkey)
3 · 4.5 g/day intravenously or IMP (Tienam; Merck, Istan-
bul, Turkey) 4 · 500 mg/day intravenously]. Treatment was
planned for 14 days. For osteomyelitis, treatment was admin-
istered for 28 days, counting from the time of debridment if
performed. However, after total excision of infected bone,
5 days of treatment were considered adequate depending on
the clinical response.
The antibiotic regimen was modiﬁed according to culture
and susceptibility results. In cases with resistant Enterococci
or methicillin-resistant Staphylococcus aureus (MRSA) glyco-
peptides were added to the therapy.
Study end-points
The primary end-point was the clinical response to the anti-
biotics tested. The complete regression of symptoms and
signs such as purulent discharge, erythema or induration that
were present before the treatment was recorded as ‘cure’
or ‘response’, whereas the persistence or progression of
such ﬁndings was recorded as ‘failure’.
Secondary end-points included relapse rate at the end of
the 2 months follow-up. Patients who responded at ﬁrst but
whose symptoms and signs recurred after the completion of
treatment were categorized as ‘relapse’. A complete vs. par-
tial eradication of microorganisms present before treatment
was recorded as a ‘complete’ vs. ‘partial’ microbiological
response, respectively.
Statistical analysis
SPSS 14.0 was used for the statistical analysis (SPSS Inc., Chi-
cago, IL, USA). For comparison of variables, parametric or
nonparametric tests were used, depending on the type and
distribution of data. p <0.05 was considered statistically sig-
niﬁcant.
Results
Demographic and clinical ﬁndings
Sixty-eight patients were eligible for the study. Four patients
refused to participate in the study; 64 patients were random-
ized (31 to Pip-Tazo and 33 to IMP). Within 1 week of ran-
domization, two patients (one in each group) were excluded
as a result of an allergic reaction. The remaining 62 patients
(39 male, 23 female) completed the study (Fig. 1).
Demographic and clinical characteristics of the patients
are summarized in Table 1. Study groups were comparable
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in terms of age, sex, duration of diabetes, size of ulcer, and
other clinical ﬁndings. Twenty-two (73.3%) in the Pip-Tazo
group and 26 (81.2%) in the IMP group had DFI with an
associated osteomyelitis. The duration of infection before
inclusion in the study was 30 (7–50) days and 40.5 (3–120)
days in the Pip-Tazo and IMP groups, respectively. The infec-
tion was microbiologicaly documented in approximately 80%
of patients in both groups. The mean duration of therapy
was 21 (14–42) days for patients in the Pip-Tazo group and
24 (14–45) days for patients in the IMP group (p 0.431). For
three patients with MRSA isolates (two in the Pip-Tazo and
one in the IMPgroup), a glycopeptide was added to the treat-
ment. Study treatment was not changed for any other
patient.
Clinical and microbiological outcomes
A successful clinical response was seen in 14 (46.7%) patients
in the Pip-Tazo group and in nine (28.1%) patients in the IMP
group [relative risk (RR) 1.6 (95% CI 0.84–3.25), p 0.130]
(Table 2).
Assessed for eligibility (n = 68) 
Excluded 
  (refused to participate) (n = 4) 
Analyzed  (n = 30) 
Discontinued intervention (n = 1)
allergic reaction
Allocated to Pip-Tazo (n = 31) 
Discontinued intervention (n = 1)
allergic reaction
Allocated to IMP (n = 33) 





Randomized (n = 64) 
FIG. 1 Trial ﬂow-diagram.
TABLE 1. Demographic and clini-




(n = 32) p value
Age (median, range) (years) 58.3 (47–72) 58.5 (37–80) 0.942
Sex (n, %)
Female 11 (36.7) 12 (37.5) 0.945
Male 19 (63.3) 20 (62.5)
Co-morbidity (n, %) 20 (66.7) 22 (68.8) 0.810
Duration of diabetes (median, range) (years) 13.5 (3–30) 10.5 (0–30) 0.063
Prior antibiotic usage (median, range) (days) 21 (14–42) 24 (14–45) 0.431
Prior hospitalization (n, %) 15 (50) 10 (31.3) 0.213
Anti-diabetic usage before hospitalization (n, %)
Oral anti-diabetics 14 (46.7) 18 (56.3) 0.300
Insulin 16 (53.3) 12 (37.5)
Wagner class (n, %)
Class 2 5 (16.7) 4 (12.5) 0.751
Class 3 15 (50) 19 (59.4)
Class 4 10 (33.3) 9 (28.1)
Width of ulcer (median, range) (mm) 32.5 (20–50) 30 (5–50) 0.847
Depth of ulcer (median, range) (mm) 25 (15–35) 20 (2–35) 0.103
Duration of infection (median, range) (days) 30 (7–50) 40.5 (3–120) 0.693
Ulcer duration before therapy (median, range) (days) 40.5 (3–120) 30 (7–150) 0.926
Type of infection (n, %)
Osteomyelitis 22 (73.3) 26 (81.2) 0.05
Deep soft-tissue infection/infected ulcer 8 (26.7) 6 (18.8)
Presence of ischaemia 5 (16.7) 7 (21.8)
Duration of therapy (median, range) (days) 21 (14–42) 24 (14–45) 0.431
Microbiologically documented infection (n, %) 24 (80) 25 (78.1) 1.000
VAC treatment (n, %) 3 (10) 4 (12.5) 1.000
Pip-Tazo, piperacillin/tazobactam; IMP, imipenem/cilastatin; VAC, vacuum assisted closure.
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During 2 months follow-up, two patients in the IMP group
and none in the PIP-Tazo group relapsed, excluding the
patients who had amputation [RR 2 (0.94–4.24), p 0.058].
Twenty-four patients in the Pip-Tazo group and 25
patients in the IMP group had a positive culture. Among
these, 47 (96%) had complete and two (4%) had partial
microbiological response. Microbiological response rates
were similar in the two groups (Table 2).
Surgical outcomes
Sixty-four percent of patients (40/62) had amputations, 47%
of which were minor digital amputations. Amputations were
transmetatarsal in 10%, tarsometatarsal (i.e. Chopart) in 20%,
and below the knee in 22.5% of the patients. Amputation
was performed in 30 patients for uncontrolled infection, and
in ten patients for ischaemia or non-infectious reasons such
as Chopart. Patients who had amputations despite appropri-
ate therapy were recorded as ‘failures’.The addition of
vancomycin was not considered as ‘failure’.
As shown in Table 2, there was no statistically signiﬁcant
difference in amputation rates between the Pip-Tazo and
IMP groups (60% vs. 68.8%, p 0.739).
Isolated microorganisms
Eighty-nine pathogens were isolated; 43% were Gram-posi-
tive and 57% Gram-negative bacteria. No anaerobic bacteria
were isolated as a result of inappropriate specimen collec-
tion. Infection was monomicrobial in 38.7% and polymicrobial
in 40.3% of patients.
The microorganisms isolated are shown in Table 3.
Pseudomonas aeruginosa (29.4%) was the most common
pathogen isolated from Wagner class 3 wounds, followed by
coagulase negative staphylococcus (CNS) (23.5%) and Escheri-
chia coli (14.7%). Enterococcus faecalis (21.1%) was the most
common pathogen isolated from Wagner class 4 wounds fol-
lowed by Morganella morganii (15.8%) and Streptococcus spp.
(10.6%). The most common pathogens isolated from Wagner
class 2 wounds were CNS (55.6%) followed by Streptococ-
cus spp. (22.2%), and S. aureus (22%).
Side effects
Thirty percent (n = 9) of the patients in the Pip-Tazo group
and 9.4% (n = 3) in the IMP group experienced side effects
(p 0.055). One patient from each group experienced a
severe allergic reaction that required treatment interruption.
Side effects in the treatment groups are summarized in
Table 2.
Discussion
In the present study, we compared two broad-spectrum anti-
biotic regimens, Pip-Tazo and IMP, for the treatment of DFI.
The clinical response rate was higher among the patients
who received Pip-Tazo than those who received IMP (RR
TABLE 2. Clinical response, side effects, and surgical inter-




(n = 32) p value
Clinical response 14 (46.7) 9 (28.1) 0.130
Relapse 0/14 2/9 (2.2) 0.058
Microbiological response
Complete response 23/24 (95.8a) 24/25 (96a) 1.000
Partial response 1/24 (4.2a) 1/25 (4a)
Surgical intervention
None 3 (10) 4 (12.5) 0.739
Debridement 5 (16.7) 4 (12.5)
Ray resection 4 (13.3) 2 (6.3)
Amputation 18 (60) 22 (68.8)
Side effects
Total 9 (30)b 3 (9.4) 0.055
Hepatotoxicityc 5 (16.7) 1 (3.1)
Nephrotoxicityd 6 (20) 1 (3.1)
Hematological side effects 2 (6.7) –
Other (nausea) – 1 (3.1)
Data are given as n (%).
Pip-Tazo, piperacillin/tazobactam; IMP, imipenem/cilastatin.
aPercentage of patients with positive culture.
bBecause one or more patients had more than one side effect in Pip-Tazo
group, the total number of patients with any side effect is smaller than the total
number patients who had different events.
cHepatotoxicity is deﬁned as an increase in either (a) alanine transaminase level
more than three times the upper limit of normal, (b) alkaline phophatase level
more than twice the upper limit of normal, or (c) total bilirubin level more than
twice the upper limit of normal when associated with increased alanine transam-
inase or alkaline phophatase.
dNephrotoxicity is deﬁned as an elevated level of serum creatinine over the
upper limit of normal.




(n = 32) p value
Total Gram-positive 20(66.6) 18 (56.2) 0.400
Total Gram-negative 23 (76.6) 28 (87.5) 0.264
Susceptible Gram-positives 18/20 (90) 17/18(94.4) 0.607
Susceptible Gram-negatives 23/23 (100) 28/28 (100) 1.000
Streptococcus spp. 4 (13.3) 4 (12.5)
Streptococcus aureus 1 (3.3) 4 (12.5) 0.305
CNS 11 (36.7) 4 (12.5) 0.053
Enterococcus spp.
Enterococcus feacalis 3 (10) 3 (9.4) 0.736
Enterococcus avium 1 (3.3) 2 (6.3)
Enterococcus feaceium 0 (0) 1(3.1)
Escherichia coli 3 (10) 4 (12.5) 1.000
Pseudomonas aeruginosa 7 (23.3) 6 (18.8) 0.759
Acinetobacter baumanni 0 (0) 3 (9.4) 0.238
Morganella morganii 4 (13.3) 3 (9.4) 0.703
Proteus spp. 1 (3.3) 4 (12.5) 0.318
Klebsiella spp. 2 (6.7) 2 (6.2) 0.998
Enterobacter cloaca 2 (6.7) 2 (6.2) 1.000
Citrobacter freundii 2 (6.7) 0 (0) 0.230
Gram-negative
nonfermentative bacilli
0 (0) 1 (3.1) 1.000
Other 2 (6.7) 3 (9.4) 0.789
No microorganism isolated 6 (20) 7 (21.9)
Data are given as n (%).
Pip-Tazo, piperacillin/tazobactam; IMP, imipenem/cilastatin; CNS, coagulase nega-
tive staphylococcus.
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1.6), but the 95%CI included inferiority and superiority
(0.84–3.25). There was no signiﬁcant difference between the
treatment groups with regard to microbiological response,
relapse and amputation rates. Side effects were more com-
monly seen with Pip-Tazo, although most of them were mild
and reversible.
In previous reports, Pip-Tazo and IMP were often the ﬁrst
choice antibiotic in life- or extremity-threatening DFI [12]. In
three trials comparing intravenous regimens, no particular
regimen was found to be superior to another [13–15]. One
study evaluating the effectiveness of Pip-Tazo in DFI
reported a 97% (22/23) response rate [16]. In another study
comparing Pip-Tazo and ertapenem in DFI, treatment suc-
cess was similar with the two regimens [11]. In a multicentre
trial comparing Pip-Tazo and ampicillin/sulbactam in moder-
ate to severe diabetic foot ulcers, clinical efﬁcacy rates (cure
or improvement) were equivalent (81% vs. 83%) [17]. In the
present study, efﬁcacy rates for both Pip-Tazo and IMP (47%
vs. 28%) were relatively low, which may have been a result
of the higher rate of patients with osteomyelitis or severe
disease.
Microbiological studies are important for antibiotic man-
agement in the treatment of DFI [10]. Severe, limb-threaten-
ing or chronic infections are almost always polymicrobial
[4,5,18–20] and Gram-negative rods and anaerobic organisms
are frequently isolated together with Gram-positive cocci
[4,11,21]. In the present study, the rate of polymicrobial
infection was 40%, whereas 38% of the infections were
monobacterial. Gram-negative bacteria were the most com-
mon (57%) pathogens, which is similar to the ﬁndings
reported in previous studies [11,19,20,22,23]. This high rate
can be attributed to the fact that patients with advanced dis-
ease and prior hospitalization/antibiotic use are usually
referred to our centre. P. aeruginosa, E. coli, Enterococcus spp.,
Acinetobacter baumannii, and Klebsiella spp. were the most
common microorganisms isolated in patients with a history
of prior antibiotic usage, which is in accordance with other
published reports [24,25].
The duration of treatment in severe or extremity threat-
ening infections is based on the severity of infection [6,15].
There are no well-accepted guidelines for treating DFI asso-
ciated with osteomyelitis [6]. The duration of therapy was
28–45 days in our patients with osteomyelitis There was no
difference in duration of therapy between the two groups.
The daily cost of Pip-Tazo was approximately €186 whereas
that of IMP was €224.
In the present study, side effects included nephrotoxicity,
hepatotoxicity, leukopenia and thrombocytopenia. However,
two patients (one in each group) were excluded from the
study as a result of severe allergic reaction. The overall side
effect rate was 30% in the Pip-Tazo group and 9.4% in the
IMP group. Several previous studies have also reported
higher rates of side effects with Pip-Tazo than IMP, which
were mostly mild and reversible [11,13,16,20,26]. According
to biochemical markers, the number of patients who had
hepatotoxicity and/or nephrotoxicity was 11 in the Pip-Tazo
group and two in the IMP group. However, because hepato-
toxicty and nephrotoxity may be caused by diabetes, it is dif-
ﬁcult to be sure of the signiﬁcance of these results.
DFI is best managed by a dedicated team via appropriate
consultations [3,27,28]. Patients with severe infections or
ischaemia should be hospitalized and closely monitored
[4,21] and this was carried out in the present study. Optimal
wound care was given by an experienced nurse, who was a
member of the study group.
As far as we know, this is the ﬁrst study comparing Pip-
Tazo and IMP head-to-head in a prospective and randomized
setting in a population of moderate to severe DFI with oste-
omyelitis. The major limitations of the study were the rela-
tively small sample size and the open-label design. The
implication of the small sample size of the study is that,
although we found a difference between the treatment regi-
mens with an advantage to Pip-Tazo, the 95% CI for this dif-
ference includes both inferiority and superiority.
In conclusion, we found that that Pip-Tazo was superior
to IMP in terms of the clinical response rate in the treatment
of moderate to severe DFI, although this difference was not
statistically signiﬁcant. Further controlled-studies with a lar-
ger sample size are required to show whether Pip-Tazo has
a signiﬁcant advantage over IMP for the treatment of moder-
ate to severe DFI.
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